Mutation analysis of p53 gene in childhood malignant solid tumors

Journal of Pediatric Surgery

Volumn 32, Issue 8, 1997, Pages 1175-1180

  Kusafuka, Takeshi ^a,b   Fukuzawa, Masahiro ^a,b   Oue, Takaharu ^a,b   Komoto, Yosuke ^a,b   Yoneda, Akihiro ^a,b   Okada, Akira ^a,b  

^a Osaka University Medical School ^*

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Hepatoblastoma; Neuroblastoma; p53 gene; Rhabdomyosarcoma; Sarcoma; Undifferentiated sarcoma of the liver; Wilms' tumor

Indexed keywords

PROTEIN P53;

ARTICLE; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; GENE MUTATION; HEPATOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NEPHROBLASTOMA; NEUROBLASTOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

EID: 0030724929     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3468(97)90677-1     Document Type: Article

References (48)

1. Isobe M, Emanuel BS, Givol D, et al: Localization of gene for human p53 tumour antigen to bind 17p13. Nature 320:84-85, 1986
2. Mcbride OW, Merry D, Givol D: The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci U S A 83:130-134, 1986
3. Fields S, Jang S: Presence of a potent transcription activating sequence in the p55 protein. Science 249:1046-1049, 1990
4. Raycroft L, Wu H, Lozano G: Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249:1049-1051, 1990
5. Nigro JM, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705-708, 1989
6. Hollstein M, Sidransky D, Vogelstein B, et al: P53 mutations in human cancers. Science 253:49-53, 1991
7. Caron de Fromentel C, Soussi T: TP53 tumor suppressor gene: A model for investigating human mutagenesis. Genes Chromosomes Cancer 4:1-15, 1992
8. Levine AJ, Momand J, Finley CA: The p53 tumour suppressor gene. Nature 351:453-456, 1991
9. Xiong Y, Hannon GJ, Zhang H, et al: p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993
10. Dulic V, Kaufmann WK, Wilson SJ, et al: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023, 1994
11. Harper JW, Adami GR, Wei N, et al: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816, 1993
12. el Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993
13. Lowe SW, Schmitt EM, Smith SW, et al: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849, 1993
14. Clarke AR, Purdie CA, Harrison DJ, et al: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852, 1993
15. Chang F, Syrjanen S, Syrjanen K: Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13:1009-1022, 1995
16. Bokemeyer C, Kuczyk MA, Sehrt J: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 330:865, 1994
17. Casson AG, Monolopoulos B, Troster M, et al: Clinical implication of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer. Am J Surg 167:52-57, 1994
18. Mitsudomi T, Oyama T, Kusano T, et al: Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 85:2018-2023, 1993
19. Ryberg D, Kure E, Lystad S, et al: p53 mutations in lung tumors: Relationship to putative susceptibility markers for carcinoma. Cancer Res 54:1551-1555, 1994
20. Evans AE, D'Angio GJ, Randolph JA: A proposed staging for children with neuroblastoma: Children's Cancer Study Group A. Cancer 27:374-378, 1971
21. D'Angio GJ, Breslow N, Beckwith JB, et al: Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer 64:349-360, 1989
22. Morita K, Okabe I, Uchino J, et al: The proposed Japanese TNM classification of primary liver carcinoma in infants and children. Jpn J Clin Oncol 13:361-370, 1983
23. Maurer HM: The intergroup Rhabdomyosarcoma Study (N.I.H.): Objectives and clinical staging classification. J Pediatr Surg 10:977-978, 1975
24. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning. New York, NY, Cold Spring Harbor Laboratory Press, 1989, vol 2, pp 9.16-9.19
25. Oda H, Nakatsuru Y, Imai Y, et al: A mutational hot spot in the p53 gene is associated with hepatoblastomas. Int J Cancer 60:786-790, 1995
26. Li FP, Fraumeni JF, Mulvihill JJ, et al: A cancer family syndrome in twenty-four families with Li-Fraumeni syndrome. Cancer Res 48:5358-5362, 1988
27. Vogelstein B, Kinzler K: p53 function and dysfunction. Cell 70:523-526, 1992
28. Pavletich NP, Chambers KA, Pabo CO: The DNA binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev 7:2556-2564, 1993
29. Imamura J, Bartran CR, Berthold F, et al: Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res 53:4053-4058, 1993
30. Vogan K, Bernstein M, Leclerc J, et al: Absence of p53 gene mutation in primary neuroblastomas. Cancer Res 53:5269-5273, 1993
31. Komuro H, Hayash Y, Kawamura M, et al: Mutations of the p53 gene are involved in Ewing' sarcomas but not in neuroblastomas. Cancer Res 53:5284-5288, 1993
32. Ohgaki H, Eibl RH, Schwab M, et al: Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog 8:74-80, 1993
33. Hosoi G, Hara J, Okamura T, et al: Low frequency of the p53 gene mutations in neuroblastoma. Cancer 73:3087-3093, 1994
34. Waber PG, Chen J, Nisen PD: Infrequency of ras, p53, WT1, or RB gene alterations in Wilms tumors. Cancer 72:3732-3738, 1993
35. Malkin D, Sexsmith E, Yeger H, et al: Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor. Cancer Res 54:2077-2079, 1994
36. Bardeesy N, Falkoff D, Petruzzi M, et al: Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nature Genet 7:91-97, 1994
37. Kar S, Jaffe R, Carr BI: Mutation at codon 249 of p53 gene in a human hepatoblastoma. Hepatology 18:566-569, 1993
38. Kennedy SM, Macgeogh C, Jaffe R, et al: Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations. Hum Pathol 25:438-442, 1994
39. Toguchida J, Yamaguchi T, Ritchie B, et al: Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52:6194-6199, 1992
40. Stratton MR, Moss S, Warren W, et al: Mutation of the p53 gene in human soft tissue sarcomas: Association with abnormalities of the RB1 gene. Oncogene 5:1297-1301, 1990
41. Mulligan LM, Matlashewski GJ, Scrable HJ, et al: Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci U S A 87:5863-5867, 1990
42. Felix CA, Kappel CC, Mitsudomi T, et al: Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 52:2243-2247, 1992
43. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238, 1990
44. Srivastava S, Zou A, Pirollo K, et al: Germ line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747-749, 1990
45. Diller L, Sexsmith E, Gottlieb A, et al: Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 95:1606-1611, 1995
46. Stocker JT, Ishak KG: Undifferentiated (embryonal) sarcoma of the liver. Cancer 42:336-348, 1978
47. Leuschner I, Schmidt D, Harms D: Undifferentiated sarcoma of the liver in childhood: Morphology, flow cytometry, and literature review. Hum Pathol 21:68-76, 1990
48. Harris CC: p53: At the crossroads of molecular carcinogenesis and risk assessment. Science 262:1980-1981, 1993